Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100595 | 0.97 | NT5E (0.66) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL28740274 | 0.95 | NT5E (0.63) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL19370293 | 0.85 | NT5E (0.73) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL19370224 | 0.85 | NT5E (0.73) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL19349798 | 0.82 | NT5E (0.69) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL19366735 | 0.81 | NT5E (0.70) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL19366693 | 0.81 | NT5E (0.70) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL30440145 | 0.81 | NT5E (0.70) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL19100892 | 0.81 | NT5E (0.70) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL19100848 | 0.78 | NT5E (0.71) | NT5EADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885ADORA1 39/4885ADORA3 35/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885ADORA1 40/4885ADORA3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.